Measurement of breathlessness in clinical trials in patients with chronic heart failure: The need for a standardized approach: A systematic review

European Journal of Heart Failure

Volumn 12, Issue 2, 2010, Pages 137-147

  Johnson, Miriam J ^a,b   Oxberry, Stephen G ^b   Cleland, John G F ^b   Clark, Andrew L ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Breathlessness; Chronic heart failure; Measurement tools

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DYSPNEA; HEART FAILURE; HUMAN; LUNG EDEMA; MEASUREMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; DYSPNEA; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 75149113556     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp194     Document Type: Article

References (88)

1. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321-340.
2. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Fillipatos G, Gheorghiade M. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008;29:816-824.
3. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007;101: 399-410.
4. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007; 21:177-191.
5. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56:248-255.
6. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998;113:619-624.
7. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989;64:50-55.
8. Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 2000;82:800-805.
9. Corner J, O'Driscoll M. Development of a breathlessness assessment guide for use in palliative care. Palliat Med 1999;13:375-384.
10. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-107. (Pubitemid 19081188)
11. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-778.
12. Tu SP, McDonell MB, Spertus JA, Steele BG, Fihn SD. A new self-administered questionnaire to monitor health-related quality of life in patients with COPD. Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 1997;112:614-622.
13. Weaver TE, Narsavage GL, Guilfoyle MJ. The development and psychometric evaluation of the Pulmonary Functional Status Scale: an instrument to assess functional status in pulmonary disease. J Cardiopulm Rehabil 1998;18:105-111.
14. Garrod R, Paul EA, Wedzicha JA. An evaluation of the reliability and sensitivity of the London Chest Activity of Daily Living Scale (LCADL). Respir Med 2002;96: 725-730.
15. Lareau SC, Meek PM, Roos PJ. Development and testing of the modified version of the pulmonary functional status and dyspnea questionnaire (PFSDQ-M). Heart Lung 1998;27:159-168.
16. Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the 'Quality-of-life for Respiratory Illness Questionnaire (QOL-RIQ)': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med 1997;91:297-309.
17. Jacobs JE, Maille AR, Akkermans RP, van WC, Grol RP. Assessing the quality of life of adults with chronic respiratory diseases in routine primary care: construction and first validation of the 10-Item Respiratory Illness Questionnaire-monitoring 10 (RIQ-MON10). Qual Life Res 2004;13:1117-1127.
18. Hiratsuka T, Kida K. Quality of life measurements using a linear analog scale for elderly patients with chronic lung disease. Intern Med 1993;32:832-836.
19. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A(Suppl. 1):S51-S58.
20. Dougan CF, Connell CO, Thornton E, Young CA. Development of a patient-specific dyspnoea questionnaire in motor neurone disease (MND): the MND dyspnoea rating scale (MDRS). J Neurol Sci 2000;180:86-93.
21. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest 2003;124:2182-2191.
22. Keresztes P, Holm K, Penckofer S, Merritt S. Measurement of functional ability in patients with coronary artery disease. J Nurs Meas 1993;1:19-28.
23. Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs 1989;14:323-325.
24. Mador MJ, Kufel TJ. Reproducibility of visual analog scale measurements of dyspnea in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:82-87.
25. Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care 1998;7:200-204.
26. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-98.
27. Borg G, Linderholm H. Exercise performance and perceived exertion in patients with coronary insufficiency, arterial hypertension and vasoregulatory asthenia. Acta Med Scand 1970;187:17-26.
28. McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J 1978;2:241-243.
29. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990;142:1009-1014.
30. Powers J, Bennett SJ. Measurement of dyspnea in patients treated with mechanical ventilation. Am J Crit Care 1999;8:254-261.
31. Dorman S, Jolley C, Abernethy A, Currow D, Johnson M, Farquhar M, Griffiths G, Peel T, Moosavi S, Byrne A, Wilcock A, Alloway L, Bausewein C, Higginson I, Booth S. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009;23:213-227.
32. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
33. Abdulla J, Kober L, Christensen E, Torp-Pedersen C. Effect of beta-blocker therapy on functional status in patients with heart failure-a meta-analysis. Eur J Heart Fail 2006;8:522-531.
34. Abdulla J, Pogue J, Abildstrom SZ, Kober L, Christensen E, Pfeffer MA, Yusuf S, Torp-Pederson C. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction-a meta-analysis. Eur J Heart Fail 2006;8:90-96.
35. Paterna S, Di PP, Parrinello G, Amato P, Cardinale A, Follone G, Giubilato A, Licata G. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-313. (Pubitemid 30670731)
36. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol 1983;2:755-763.
37. Argenziano L, Morisco C, Trimarco B, Marino C, Bedoschi D, Boscani PF. Efficacy and safety of torsemide in patients with moderate congestive heart failure. Curr Ther Res 1998;59:697-708.
38. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J 1995;16: 1892-1899.
39. Williams SG, Wright DJ, Marshall P, Reese A, Tzeng BH, Coats AJ, Lip BT. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 2003;89:1085-1086.
40. Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997;29:147-152. (Pubitemid 27028732)
41. Albert NM, Buchsbaum R, Li J. Randomized study of the effect of video education on heart failure healthcare utilization, symptoms, and self-care behaviors. Patient Educ Couns 2007;69:129-139.
42. Weiner P, Waizman J, Magadle R, Berar-Yanay N, Pelled B. The effect of specific inspiratory muscle training on the sensation of dyspnea and exercise tolerance in patients with congestive heart failure. Clin Cardiol 1999;22:727-732.
43. Latta D, Finnamore VP, Dalton K, Allman S. An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/ potassium chloride in the treatment of mild congestive cardiac failure. J Int Med Res 1990;18(Suppl. 2):10B-16B.
44. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991;121:1956-1964.
45. Warrington SJ, Sinclair AJ, Johnston A. Effects of single doses of a 20 mg frusemide/2.5 mg amiloride combination, 20 mg frusemide and placebo on plasma and urine electrolytes in healthy men.JInt Med Res 1990;18(Suppl. 2):3B-9B.
46. Rozkovec A, Papouchado M, James MA, Kendrick AH, Clarke LM, Rees JR. The relationship of symptoms to performance in paced patients with breathlessness. Eur Heart J 1989;10:63-69.
47. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017-1025.
48. Egea CJ, Aizpuru F, Pinto JA, Ayuela JM, Ballester E, Zamarron C, Sojo A, Montserrat JM, Barbe F, Alonso-Gomez AM, Rubio R, Lobo JL, Duran-Cantolla J, Zorilla V, Nunez R, Cortes J, Jimenez A, Cifrian J, Ortega M, Carpizo R, Sanchez A, Teran J, Iglesias L, Fernandez C, Alonso ML, Cordero J, Roig E, Perez F, Muxi A, Gude F, Amaro A, Calvo U, Masa JF, Utrabo I, Porras Y, Lanchas I, Sanchez E. Cardiac function after CPAP therapy in patients with chronic heart failure and sleep apnea: a multicenter study. Sleep Med 2008;9:660-666.
49. Dall'Ago P, Chiappa GR, Guths H, Stein R, Ribeiro JP. Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J Am Coll Cardiol 2006;47:757-763.
50. Beniaminovitz A, Lang CC, LaManca J, Mancini DM. Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. J Am Coll Cardiol 2002;40: 1602-1608.
51. Oka RK, De MT, Haskell WL, Botvinick E, Dae MW, Bolen K, Chatterjee K. Impact of a home-based walking and resistance training program on quality of life in patients with heart failure. Am J Cardiol 2000;85:365-369.
52. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50: 2136-2144.
53. Lindvall K, Eriksson SV, Lagerstrand L, Sjogren A. Efficacy and tolerability of trans-dermal nitroglycerin in heart failure. A noninvasive placebo controlled double-blind cross over study. Eur Heart J 1988;9:373-379
54. The German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet 1988;1:489-493.
55. Allman S, Norris RJ. An open, parallel group study comparing a frusemide/ amiloride diuretic and a diuretic containing cyclopenthiazide with sustained release potassium in the treatment of congestive cardiac failure-a multicentre general practice study. J Int Med Res 1990;18(Suppl. 2):17B-23B.
56. Baligadoo SJ, Subratty H, Manraz M, Tarral A, Maiti D, Murday M. Effects of enox-imone on quality of life. Int J Cardiol 1990;28(Suppl. 1):S29-S32.
57. Cahalin LP, Semigran MJ, Dec GW. Inspiratory muscle training in patients with chronic heart failure awaiting cardiac transplantation: results of a pilot clinical trial. Phys Ther 1997;77:830-838.
58. Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986;2:770-772.
59. Guyatt GH, Sullivan MJ, Fallen EL, Tihal H, Rideout E, Halcrow S, Nogradi S, Townsend M, Taylor DW. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988;61:371-375.
60. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. Eur J Heart Fail 2002;4:753-756.
61. Kholeif MA, Pringle S, Kesson E, Murray G, Kennedy JA, Lorimer AR, Stock JK, Brown JJ. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J Cardiovasc Pharmacol 1991;18(Suppl. 2):S180-S183.
62. Laoutaris I, Dritsas A, Brown MD, Manginas A, Alivizatos PA, Cokkinos DV. Inspiratory muscle training using an incremental endurance test alleviates dyspnea and improves functional status in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004;11:489-496.
63. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schlemen MM, Robertson AD, Gorcynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000;36: 501-508.
64. McConnell TR, Mandak JS, Sykes JS, Fesniak H, Dasgupta H. Exercise training for heart failure patients improves respiratory muscle endurance, exercise tolerance, breathlessness, and quality of life. J Cardiopulm Rehabil 2003;23:10-16.
65. Meyer K, Schwaibold M, Westbrook S, Beneke R, Hajric R, Gornandt L, Lehmann M, Roskamm H. Effects of short-term exercise training and activity restriction on functional capacity in patients with severe chronic congestive heart failure. Am J Cardiol 1996;78:1017-1022. (Pubitemid 126658679)
66. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-520.
67. Naylor JM, McLean A, Chow CM, Heard R, Ting I, Avolio A. A modified postural drainage position produces less cardiovascular stress than a head-down position in patients with severe heart disease: a quasi-experimental study. Aust J Physiother 2006;52:201-209.
68. Pozehl B, Duncan K, Hertzog M. The effects of exercise training on fatigue and dyspnea in heart failure. Eur J Cardiovasc Nurs 2008;7:127-132.
69. Ramsay F, Crawford RJ, Allman S, Bailey R, Martin A. An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/ potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients. Curr Med Res Opin 1988;10:682-689.
70. Ribner HS, Sagar KB, Glasser SP, Hsieh AM, Dills CV, Larkin S, DeSilva J, Whalen JJ. Long-term therapy with benazepril in patients with congestive heart failure: effects on clinical status and exercise tolerance. J Clin Pharmacol 1990; 30:1106-1111.
71. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994;23: 393-400.
72. Schofield PM, Brooks NH, Lawrence GP, Testa HJ, Ward C. Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. Br J Clin Pharmacol 1991;31:25-32.
73. Yu DS, Lee DT, Woo J, Hui E. Non-pharmacological interventions in older people with heart failure: effects of exercise training and relaxation therapy. Gerontology 2007;53:74-81. (Pubitemid 46279733)
74. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2005;4:198-206.
75. Ekman I, Boman K, Olofsson M, Aires N, Swedberg K. Gender makes a difference in the description of dyspnoea in patients with chronic heart failure. Eur J Cardio-vasc Nurs 2005;4:117-121.
76. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. Acta Anaesthesiol Scand 2001;45:1067-1075.
77. Wilcock A, Crosby V, Clarke D, Tattersfield A. Repeatability of breathlessness measurements in cancer patients. Thorax 1999;54:375.
78. Subratty AH, Manraj M, Baligadoo S. A new visual analogue scale for assessment of dyspnoea in congestive heart failure. Int J Clin Pharmacol Ther 1994;32:259-261.
79. Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, Dargie H. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999;116:1208-1217.
80. Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 2004;10:188-191.
81. Karras DJ, Sammon ME, Terregino CA, Lopez BL, Griswold SK, Arnold GK. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med 2000;7:327-334.
82. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2: 105-110.
83. Improving research methodology in breathlessness: a meeting convened by the MRC clinical trials unit and the Cicely Saunders Foundation. Palliat Med 2006; 20:219-220.
84. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30A:1326-1336.
85. Zambroski CH, Lennie T, Chung ML, Heo S, Smoot T, Ziegler C. Use of the Memorial Symptom Assessment Scale-Heart Failure in heart failure patients. Circulation 2004;110(Suppl. III):III-739.
86. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758.
87. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:99-103.
88. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21:267-272.